Improved Testing for Barrett's Esophagus

August 19, 2014|

This is a companion article to the CLP feature, "The New Path Forward." Over the past few decades, there has been a dramatic increase in the incidence of esophageal cancer (EC), a highly lethal disease known to have a 5-year survival rate of just 17%. Data from the National Cancer Institute indicate that EC has increased at a pace greater than any other type of cancer, growing by 500% since the 19 Read More

NewCo on the Go: Cernostics aims to help GIs manage Barrett’s patients

April 21, 2014|

Gastroenterologists are usually quick to admit they do not have a good way to manage patients with Barrett's esophagus. They know Barrett's is a precursor to esophageal cancer, but they don't have a great way of predicting which Barrett's patients are likely to progress to esophageal cancer and which patients probably won't develop the cancer.   Cernostics (Pittsburgh), a young company taking Read More

Cernostics gets $100,000 in funding

March 25, 2014|

By Kris B. Mamula, Pittsburgh Business Times   Uptown Pittsburgh-based Cernostics Inc. will receive $100,000 in funding to advance development of its lead product, which will help diagnose patients at risk for esophageal cancer.   The Ben Franklin Technology Partners of Northeastern Pennsylvania provided the funds. Cernostics is collaborating with health care organizations worldwide to b Read More

Pittsburgh life sciences company developing diagnostic test for esophageal cancer

March 24, 2014|

By Deb Smit, NEXTpittsburgh   Pittsburgh life sciences company Cernostics is on the forefront of a diagnostic test for the early detection of esophageal cancer.   Company researchers have been working under the radar since 2010 to develop a potentially life-saving platform that will help gastroenterologists identify patients who are at risk of developing cancer of the esophagus.   G Read More

Cernostics receives 3 patents

February 11, 2014|

By Kris B. Mamula, Pittsburgh Business Times   Cancer diagnostics company Cernostics announced Tuesday it had received two patents in the United States and a third patent in Japan.   The patents pertain to different aspects of the Uptown Pittsburgh company's TissueCypher™ technology platform.   "These patents are an important part of our intellectual property strategy and pro Read More

Diagnostic developer with faster, more accurate esophageal cancer test nets follow-on funding

January 25, 2014|

By Stephanie Baum, MedCity News   Esophageal cancer is one of the fastest growing cancers in western countries and has one of the highest mortality rates among cancers. About 17,990 new cases are diagnosed in the United States each year, according to data from the American Cancer Society. More than 15,000 people die from esophageal cancer annually.   Medical device company Cernostics is Read More

Cernostics taps patient registry

January 13, 2014|

By Kris B. Mamula, Pittsburgh Business Times   Cancer diagnostics company Cernostics announced collaboration with the Academic Medical Center in The Netherlands, which will give the Oakland company access to one of the world's biggest Barrett's Esophagus patient registries in the world.   Barrett's Esophagus is a precursor to esophageal cancer, which has a five-year survival rate of just Read More

Cernostics Collaborates with Academic Medical Center in The Netherlands

January 8, 2014|

Posted on 08, Jan 2014 by Jonathan Kersting   Cernostics, a diagnostics company focused on delivering next generation cancer diagnostics through a unique approach to tissue analysis, announced today that it is collaborating with the Academic Medical Center in The Netherlands (AMC).  As part of the collaboration, AMC will be providing Cernostics with access to one of the largest Barrett's Esop Read More

Cernostics, Dutch Medical Center Collaborate on Barrett’s Esophagus-related Cancer

January 7, 2014|

NEW YORK (GenomeWeb News) – Cernostics said on Tuesday it is collaborating with the Academic Medical Center in the Netherlands to complete validation studies of the company's test for cancer in patients with Barrett's Esophagus.   AMC will provide Cernostics access to its Barrett's Esophagus patient registry, which Cernostics will use to complete studies of its TissueCypher:Barrett's. Under t Read More

Cancer Dx Firm Cernostics Raises $1.4M

December 10, 2013|

NEW YORK (GenomeWeb News) – Cancer diagnostics and prognostics firm Cernostics recently announced it raised $1.4 million in a Series B financing round.   The funds will be used to further develop and commercialize the Pittsburgh-based company's lead product called TissueCypher: Barrett's. Its technology, Cernostics said, quantifies whole slide digital images, providing more information and ac Read More

Cernostics raises $1.4M in Series B funding

December 3, 2013|

By Paul J Gough, Digital Producer   A Pittsburgh-based life sciences company has raised $1.4 million in Series B funding for its work on a next-generation cancer diagnostic tool.   Cernostics said Tuesday the funding included original investors Pittsburgh Life Sciences Greenhouse, Geisinger Health System and Novitas Capital. The $1.4 million in Series B funding announced Tuesday will go Read More

Cancer Diagnostics Company Cernostics Raises $1.4M Series B

December 3, 2013|

Cernostics Inc., which is developing cancer diagnostics, has raised $1.4 million in Series B funding as it advances a test for esophageal cancer.   Original investors participating in the round include Geisinger Health System, Novitas Capital and Pittsburgh Life Sciences Greenhouse.  Cernostics has now raised more than $6 million including grants and investments, it said. Valuation wasn't dis Read More

Cancer MDx Firm Cernostics Seeks to Raise $500K

August 17, 2012|

NEW YORK (GenomeWeb News) – Cancer molecular diagnostics firm Cernostics has filed a document with the US Securities and Exchange Commission saying it plans to raise $500,000.   The Pittsburgh-based company, which also has offices in Danville, Penn., did not respond to a request for comment, but in its Form D, it said that it raised $125,000 toward its targeted amount. Securities offered as p Read More

Cernostics Receives $100K Loan from Ben Franklin Technology Partners of Northeastern Pennsylvania

August 9, 2012|

Cernostics, Inc., a Danville, PA-based life science company developing new molecular diagnostic tests, has received a $100k loan from the Ben Franklin Technology Partners of Northeastern Pennsylvania.   Led by Mike Hoerres, CEO, and Rebecca Critchley-Thorne, Ph.D., Director of Biomarker & Diagnostic Development, the company has developed technology and intellectual property based on a sys Read More

Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests

April 6, 2011|

Multi-color fluorescence slides analyzed by Definiens Tissue Studio to provide clinicians with more complete understanding of disease state   Definiens, the number one Health Image Intelligence™ company, and Cernostics, a life sciences firm specializing in advanced cancer diagnostics, today announced a partnership to develop a unique multiplexed assay tool for the diagnosis of cancer. Read More

Pathology imaging firm Cernostics pulls in $2.6M

June 4, 2010|

Slightly under-the-radar Cernostics Inc. has raised $2.6 million in equity, debt and options, according to a regulatory filing with the Securities and Exchange Commission.   The newly rechristened Cernostics was previously known as Cernostics Pathology Inc., including in 2008 when it was spun off from Pittsburgh-based Cellumen Inc. At the time of the spinoff, Cernostics' aim was to focus on " Read More